HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MYO

Myomo, Inc. (AMEX)

Healthcare — Medical Devices

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

None 5 analysts
$1.04
(0.00%)
Target: $4.42 (325.0%)
Sign in to add MYO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$40.18M
P/E Ratio (TTM)-
Forward P/E-4.11
EPS (TTM)$-0.36
Dividend Yield-
Profit Margin-36.69%
Revenue Growth2.90%
ROE-98.53%
Debt/Equity210.65
Recommendation None
Analyst Target$4.42
Analysts5
Indexes AMEX

Technical Indicators

RSI (14)32.4
Beta1.46
SMA 20-
SMA 40-
52-Week High$2.38
52-Week Low$0.61
50-Day Avg$1.04
200-Day Avg$0.92
Avg Volume780.8K
Volume479.7K

Performance Analysis

NEUTRAL

MYO presents a mixed picture with both positive and negative indicators.

~ Trading at 25% of its 52-week range.
~ RSI at 32.4 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 2.9% year-over-year.
- Operating at a loss with -36.7% margin.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $4.42 implies 325.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:21 UTC

Back to Screener Export Report